Keyphrases
Bone Marrow Cells
100%
Multiple Myeloma
100%
Bone Marrow MSCs
100%
Mesenchymal Stromal Cells
100%
Growth Differentiation
100%
Melflufen
100%
Growth Response
100%
Melphalan
50%
Doxorubicin
40%
Cytotoxicity
30%
Osteogenesis
20%
Bortezomib
20%
MSC Differentiation
20%
Myeloma Cells
20%
Adipocyte
10%
Cell number
10%
Angiogenesis
10%
Healthy Individuals
10%
Differential Expression
10%
Novel Therapeutic Targets
10%
Osteoblast
10%
Self-renewal
10%
Therapy Outcome
10%
Vascular Network
10%
Adipogenesis
10%
Differentiation Markers
10%
Anticancer
10%
Cellular Compartments
10%
MSC Proliferation
10%
Bone Marrow Stroma
10%
Human Bone Marrow
10%
Relapsed or Refractory multiple Myeloma
10%
Multipotent Progenitors
10%
All-affected
10%
MM.1S
10%
Medicine and Dentistry
Stromal Cell
100%
Multiple Myeloma
100%
Melphalan
100%
Doxorubicin
80%
Cytotoxicity
60%
Bone Development
40%
Bortezomib
40%
Myeloma Cell
40%
Adipocyte
20%
Adipogenesis
20%
Osteoblast
20%
Angiogenesis
20%
Vascular Network
20%
Stroma
20%
Cellular Compartment
20%
Biochemistry, Genetics and Molecular Biology
Stromal Cell
100%
Melphalan
100%
Doxorubicin
80%
Cytotoxicity
60%
Coculture
40%
Bone Development
40%
Normal Human
20%
Angiogenesis
20%
Cell Count
20%
Anticancer
20%
Adipocyte
20%
Osteoblast
20%
Adipogenesis
20%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
100%
Melphalan
100%
Doxorubicin
80%
Cytotoxicity
60%
Myeloma
40%
Bortezomib
40%
Normal Human
20%